Noncontact Biventricular Mapping And Intramural Ablation In A Chronic Ovine Model Of Septal Ventricular Tachycardia
Funder
National Health and Medical Research Council
Funding Amount
$519,279.00
Summary
Ventricular tachycardia (VT), an abnormal rhythm originating from the bottom portion of the heart is the major cause of sudden death in the community. Medications are not reliably effective. Expensive (costing about $40,000 every 5 years) implanted defibrillators are very effective in terminating VT, but frequently require painful shocks. Patients who require frequent treatment from their defibrillators are considered for mapping and ablation. About half of the patients with VT have the arrhythm ....Ventricular tachycardia (VT), an abnormal rhythm originating from the bottom portion of the heart is the major cause of sudden death in the community. Medications are not reliably effective. Expensive (costing about $40,000 every 5 years) implanted defibrillators are very effective in terminating VT, but frequently require painful shocks. Patients who require frequent treatment from their defibrillators are considered for mapping and ablation. About half of the patients with VT have the arrhythmia originating from the septum (heart muscle separating the two bottom portions of the heart). This area of the heart is difficult to map from an electrical point of view. A new type of mapping system called the Ensite 3000 system enables acquisition of 3,300 virtual electrical signals from within a heart chamber using an electrode array that does not have to be in direct contact with the heart muscle surface. Our evaluation of the Ensite system in one chamber of the heart has found it to be very good in identifying areas of abnormal electrical activity. It is possible that simultaneous mapping from both sides of the septum using Ensite might be useful in mapping VT originating from the septum. Destruction of the abnormal area, once identified, is generally done using a catheter, but is limited by its ability to destroy targets deep in the heart tissue. We have designed and developed a catheter that is equipped with a needle at its tip that can create deeper lesions. In this study we will be evaluating mapping using the Ensite electrodes in both ventricles in a chronic sheep model with VT originating from the septum. The Ensite mapping will be validated with detailed contact (conventional) mapping. The prototype catheter will be used to destroy the site of origin of VT, once identified. This study should enable more effective treatment of patients with VT and improve their quality of life.Read moreRead less
Investigating Thermal And Possible Non-thermal Effects Of Radiofrequency Radiation In Brain Tissue
Funder
National Health and Medical Research Council
Funding Amount
$245,681.00
Summary
There are ongoing concerns over the possible harm from the prolonged use of mobile phone handsets. The WHO have issued a research agenda to address these concerns. This study aims to study possible mechanisms at the cellular level that was identified as a high priority research need. It aims to find out whether cellular changes that could be harmful follow as a result of slight heating effects within tissue, or whether some other, non-thermal, mechanisms may be involved.
Microwave And Laser Energies For Percutaneous Cardiac Ablation For The Cure Of Arhythmias
Funder
National Health and Medical Research Council
Funding Amount
$331,527.00
Summary
The commonest beating disorder of the heart is atrial fibrillation (AF). Whilst it can occur at any age it is more common in the elderly with 12% Australians over 70 y.o having it. AF is the cause of a third of all strokes and increases the risk of dying from any heart disease. Ventricular tachycardia (VT) is the commonest cause of death in the year after a heart attack. Currently these beating disorders are in most cases incurable and respond poorly to medications. We have developed an operatio ....The commonest beating disorder of the heart is atrial fibrillation (AF). Whilst it can occur at any age it is more common in the elderly with 12% Australians over 70 y.o having it. AF is the cause of a third of all strokes and increases the risk of dying from any heart disease. Ventricular tachycardia (VT) is the commonest cause of death in the year after a heart attack. Currently these beating disorders are in most cases incurable and respond poorly to medications. We have developed an operation for AF which is done by open heart surgery. It has been successful at curing some patients who suffer from AF and uses radiofrequency energy. The difficulty of radiofrequency energy is that it is not suitable in a large number of cases for this operation. We are developing Laser and Microwave catheters as alternatives to RF so that the success of the operation can be improved. These new microwave and laser catheters are being designed and tested to be used primarily in a minimally invasive procedure. They would be inserted via the veins with the patient under sedation. This would allow patients to go home sooner and have a recovery period of only a few days. As well as their application in the top chamber of the heart (atrium) for AF, these new energies will be adapted for minimally invasive operations in the ventricle (lower chamber) of the heart for the treatment of ventricular tachycardia. By developing a technique such as this, cure of AFand VT will be available to many more people, helping reduce the strokes, heart failure and premature deaths from these two heart conditions.Read moreRead less
Importance Of Pulmonary Venous Electrophysiology In The Development Of Atrial Fibrillation
Funder
National Health and Medical Research Council
Funding Amount
$196,219.00
Summary
(ii) Transplant rejection can be inhibited by expression in the graft of CTLA4-Fc a reagent that blocks T cell co-stimulation enhancing allo-graft acceptance (Transplantation 2000 69:1806). High-level expression for over 100 days is expected to correlate with optimal graft acceptance. Our ability to use Kunjin to express beta galactosidase for several months in vivo without inflammation illustrates the potential for this approach (CIB ref 15). Initially we intend to use P815 cells injected i.p. ....(ii) Transplant rejection can be inhibited by expression in the graft of CTLA4-Fc a reagent that blocks T cell co-stimulation enhancing allo-graft acceptance (Transplantation 2000 69:1806). High-level expression for over 100 days is expected to correlate with optimal graft acceptance. Our ability to use Kunjin to express beta galactosidase for several months in vivo without inflammation illustrates the potential for this approach (CIB ref 15). Initially we intend to use P815 cells injected i.p. into C57BL-6, where they are usually rejected within a few days. In contrast, P815 cells with Kunjin replicon-mediated CTLA4-Fc expression should survive for an extended period. Graft survival is easily monitored using FACS and anti-H-2d antibodies.Read moreRead less
Efficacy Of Coronary Sinus Ablation For The Treatment Of Atrial Fibrillation: A Randomised Controlled Study.
Funder
National Health and Medical Research Council
Funding Amount
$377,917.00
Summary
Atrial fibrillation is the most common sustained cardiac arrhythmia in the population. Left atrial catheter ablation is rapidly becoming a drug free alternative treatment for drug-resistant atrial fibrillation. The proposed study will examine whether ablation at a unique anatomical site adjacent to the left atrium (the coronary sinus) will increase procedural success compared to the conventional approach.
Obstructive Sleep Apnoea As A Risk Factor For Atrial Fibrillation
Funder
National Health and Medical Research Council
Funding Amount
$64,631.00
Summary
Atrial fibrillation is the most common sustained cardiac arrhythmia and obstructive sleep apnoea is a common sleep-related breathing disorder. It has recently been suggested that OSA increases the risk of developing AF . The aim, therefore of this study, is to determine the incidence of sleep apnoea in our population of highly symtomatic patients with atrial fibrillation and to assess the outcome on arrhythmia burden of treatment with continuous positive airways pressure (CPAP).